Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Non-Deal Roadshow (February 2019)
25 slides from Alk-abello A/s Class B's roadshow presentation, February 2019
Slide 1: Allergy solutions for life
Allergy solutions for life IR roadshow presentation February 2019
Slide 2: Allergy solutions for life
Allergy solutions for life More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing. By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage. W
Slide 3: 2018: First year with new strategy
2018: First year with new strategy • Strong progress for ALK’s new strategy • Financial results for 2018 much better than originally expected • In line with recent guidance upgrade • ALK on track to deliver accelerated growth in 2019 • Growth across all sales regions • SLIT-tablets as the key growth
Slide 4: Point of departure
Point of departure Strategy in place to transform ALK into a broader-based allergy company Foundation Transformation in process • 96 years of pioneering allergy research and treatment • Reach >1% of patients • Leader in AIT, treating 1.7m patients • Unlock the commercial potential of tablets • Portf
Slide 5: Living with allergies
Living with allergies People with allergies are often actively seeking information, products and services to help them manage their condition 50m (10%) Eligible for AIT treatment 500m (100%) Affected by allergic rhinitis ~5m (~1%) Treated with AIT Drug-free symptom Over-the-counter Prescription Alle
Slide 6: Strategy: AIT leadership and patient engagement
Strategy: AIT leadership and patient engagement Three-year strategy launched in December 2017 to transform and grow ALK Complete and Patient Succeed in Optimise and commercialise engagement North reallocate the tablet and America portfolio resources adjacencies Financial ambitions An ALK capable of
Slide 7: Succeed in North America
Strategic priority No 1 Succeed in North America 2018 tablet milestones 2019 key metrics 1,500 US prescribers ~5,000 US patients 5,200 Sales growth in North America 1,500 across main product categories 750 2,600 Increase acceptance of tablets, grow prescriber base and Rx depth 0 0 Q1-18 Q2-18 Q3-1
Slide 8: Complete and commercialise the tablet portfolio
Strategic priority No 2 Complete and commercialise the tablet portfolio 2018 milestones 2019 key metrics 80-100,000 new HDM patients initiated Maintain commercial momentum for tablets Launches in five new markets Doubling of ACARIZAX® sales Approval/launch of tree tablet in the EU Filing of tree tab
Slide 9: Build patient engagement and adjacencies
Strategic priority No 3 Build patient engagement and adjacencies 2018 milestones 2019 key metrics klarify.me launched in Germany with 20 million klarify.me messages seen ~50 products and the UK; ~1m visitors >100,000 downloads klara smartphone app launched >25,000 downloads 85,000 allergy tests Incr
Slide 10: Optimise and reallocate resources
Strategic priority No 4 Optimise and reallocate resources 2018 milestones 2019 key metrics Improved supply chain robustness; Increase production efficiency new production site strategy to improve margins Output and inventories for key Maintain supply chain quality, SCIT and SLIT-drops lines restored
Slide 11: Financial status
Financial status DKK million 2015 2016 2017 2018 2019G 2019 revenue Revenue 2,569 3,005 2,910 2,915 3,1-3,300 • Growth in all segments Gross margin 67% 67% 56% 56% • Strong tablet growth R&D 407 385 426 392 • Largely unchanged SCIT/SLIT-drops sales (% of revenue) 16% 13% 15% 13% • Growth of ~10% in
Slide 12: 2019 FY revenue outlook
2019 FY revenue outlook Higher end of 2019 range DKKm • Accelerated tablet sales across markets; modest growth in the USA • Minor contribution from consumer care • Market share gains • Stable market conditions in Europe 3,300 3,100 3,005 2,910 2,915 2,569 Lower end of 2019 range • Pricing pressure i
Slide 13: 2019 outlook
2019 outlook DKK 2018 2019 Comments actual outlook Broad-based growth across regions and products, 3.1-3.3bn particularly within tablets; increasing SCIT sales. Negative Revenue 2.915m impact from portfolio pruning and SLIT-drops. Minor positive currency impact. Incrementally higher gross margins. S
Slide 14: Appendix
Appendix IR roadshow presentation - February 2019 14
Slide 15: Pioneer since 1923 – Prevention, Diagnosis & Treatment
Pioneer since 1923 – Prevention, Diagnosis & Treatment Leader in disease modifying allergy immunotherapy (AIT) World’s 1st producer of sublingual AIT tablets (SLIT-tablets)
Slide 16: Allergy at a glance
Allergy at a glance Allergies occur when the body’s immune system overreacts to substances that are usually considered harmless, such as various types of pollen, house dust mites, moulds and animal fur. Symptoms of respiratory allergies Insufficient sleep Respiratory allergies can affect both the Al
Slide 17: ALK's current portfolio
ALK’s current portfolio Other products and services 16% SLIT- Revenue by tablets product line SCIT/ 23% SLIT-drops 61% International markets 4% North America Revenue by 20% geography Europe 76% IR roadshow presentation IR roadshow - February presentation - February2019 2019 17
Slide 18: ALK's core products
ALK’s core products Market exclusivity secured via biological manufacturing processes and know-how ALK offers products, services and resources Manufacturing footprint covering a wide range of allergies. The company Centres of excellence also has products in related areas, including early allergy int
Slide 19: Pipeline covers >80% of respiratory allergy sufferers
Pipeline covers >80% of respiratory allergy sufferers Phase I Phase II Phase III Filing Marketed ACARIZAX® Europe 2016 Adults – Allergic rhinitis and allergic asthma (HDM) Adolescents – Allergic rhinitis ACARIZAX®/ODACTRA™ North America 2017/18 Adults – Allergic rhinitis (HDM) MITICURE™ Japan* 2018
Slide 20: Q4 2018: Results in line with expectations
Q4 2018: Results in line with expectations Group performance Tablet sales • 3% top-line growth driven by tablets and Jext® • 39% growth when disregarding Q4-2017 stockpiling • Encouraging trends in SCIT/SLIT-drops sales • Underlying growth consistent with recent quarters • EBITDA reflects high activ
Slide 21: FY 2018 revenue highlights
FY 2018 revenue highlights Markets Products -7% Europe +0.3% SCIT and SLIT-drops Tablets and Jext® growth outweigh impact from Portfolio rationalisation, impact of previous product pruning and previous supply issues supply issues; market normalisation in France North America +0.5% SLIT-tablets +28%
Slide 22: 2018 performance better than originally expected
2018 performance better than originally expected Results in line with 14 December outlook upgrade DKK million 2017 2018 +1% despite Investments in Revenue 2,910 2,915 portfolio pruning; compliance ~DKK 200m & robustness Gross profit 1,642 1,633 above original outlook Gross margin 56% 56% Capacity co
Slide 23: The ALK Business Transformation
Payer Engagement The ALK Business Payers • • Recognition of severe allergies Evidence based AIT Transformation ALK • Tablet portfolio Allergist Engagement • Consolidated Specialists • Advocacy legacy portfolio • Partnerships Patient Engagement • Awareness Patients • Diagnosis • Mobilisation • Soluti
Slide 24: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements, including forecasts of future revenue, operating profit and cash flow as well as expected business-related events. Such statements are naturally subject to risks and uncertainties as various factors, some of which are
Slide 25: Thank you for your attention
Thank you for your attention Investor Relations: Per Plotnikof, Vice President, Head of Investor Relations Phone: +45 4574 7576 E-mail: ppidk@alk.net Read more: www.alk.net IR roadshow presentation - February 2019 25